- Home
- FMAC vs PLX Comparison
FMAC vs PLX Comparison
Compare FMAC & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FMAC | PLX |
|---|---|---|
| Founded | N/A | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.5M | 168.4M |
| IPO Year | 2026 | 1996 |
Fundamental Metrics
Financial Performance| Metric | FMAC | PLX |
|---|---|---|
| Price | $9.97 | $2.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 3.4K | ★ 641.2K |
| Earning Date | N/A | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.22 |
| Revenue | N/A | ★ $52,744,000.00 |
| Revenue This Year | N/A | $36.81 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $10.82 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.96 | $1.36 |
| 52 Week High | $10.02 | $3.19 |
Technical Indicators
Market Signals| Indicator | FMAC | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 46.43 | 64.79 |
| Support Level | N/A | $2.06 |
| Resistance Level | N/A | $2.42 |
| Average True Range (ATR) | 0.01 | 0.10 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 28.57 | 83.38 |
Price Performance
Historical ComparisonAbout FMAC Future Money Acquisition Corporation Ordinary Shares
Future Money Acquisition Corp is a blank check company formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.